Immune checkpoint blockade (ICB) that targets programmed cell death protein 1 (PD-1) and its ligand, programmed death ligand-1 (PD-L1), is the most attractive immunotherapy in restoring the anti-tumor immune response. Here, PDCD1 is linked to neoplasm.